Maze Therapeutics Inc.
06/10/2026 | Press release | Distributed by Public on 06/10/2026 14:16
Proxy Results (Form 8-K)
| Item 5.07. |
Submission of Matters to a Vote of Security Holders. |
On June 8, 2026, Maze Therapeutics, Inc. (the "Company") held its 2026 annual meeting of stockholders (the "Annual Meeting"). 44,660,029 shares of common stock, representing approximately 89.75% of the total outstanding shares entitled to vote at the Annual Meeting, were present virtually or represented by proxy, which constituted a quorum for the transaction of business. The Company's stockholders who were present virtually or represented by proxy voted on two proposals at the Annual Meeting, each of which is described below and more fully in the Company's definitive proxy statement filed with the United States Securities and Exchange Commission on April 28, 2026 (the "Proxy Statement").
At the Annual Meeting, the Company's stockholders voted on the following proposals:
| 1. |
To elect each of Jason Coloma, Ph.D. and Neil Kumar, Ph.D. as a Class I director to serve until the Company's 2029 annual meeting of stockholders and until such director's successor has been duly elected and qualified, or until such director's earlier death, resignation, disqualification, retirement, or removal. |
| 2. |
To ratify the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the year ending December 31, 2026. |
The final voting results for each of these proposals are as follows:
Proposal 1: Election of Directors.
|
Nominee |
Votes For | Votes Withheld | Broker Non-Votes | |||||||||
|
Jason Coloma, Ph.D. |
35,792,536 | 5,926,467 | 2,941,026 | |||||||||
|
Neil Kumar, Ph.D. |
34,056,425 | 7,662,578 | 2,941,026 | |||||||||
Each of the two nominees for director was elected to serve until the Company's 2029 annual meeting of stockholders and until such director's successor has been duly elected and qualified, or until such director's earlier death, resignation, disqualification, retirement, or removal.
Proposal 2: Ratification of Appointment of Independent Registered Public Accounting Firm.
|
Votes For |
Votes Against |
Abstentions |
Broker Non-Votes |
|||
| 44,557,778 | 728 | 101,523 | 0 |
The Company's stockholders ratified the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the year ending December 31, 2026.
Maze Therapeutics Inc. published this content on June 10, 2026, and is solely responsible for the information contained herein. Distributed via EDGAR on June 10, 2026 at 20:16 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]